The use of intravenous injection of cTfRMAb-TNFR, a drug designed to ferry the TNFR2 fusion protein [56] across the BBB using the transferrin receptor (TfR), resulted in reduced infarct volumes and reduced neural deficits 1 and 7 days post-stroke, whereas etanercept had no effect [56]. This evidence concerns the gene TNFRSF1A and stroke disorder.